1,681 Shares in ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) Bought by Belpointe Asset Management LLC

Belpointe Asset Management LLC acquired a new stake in ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO – Get Rating) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 1,681 shares of the company’s stock, valued at approximately $51,000.

Several other hedge funds have also made changes to their positions in the business. CWM LLC acquired a new stake in shares of ALPS Medical Breakthroughs ETF during the fourth quarter worth $55,000. International Assets Investment Management LLC acquired a new stake in shares of ALPS Medical Breakthroughs ETF in the 4th quarter worth $202,000. DAVENPORT & Co LLC purchased a new stake in shares of ALPS Medical Breakthroughs ETF in the fourth quarter valued at about $18,490,000. Citadel Advisors LLC acquired a new position in shares of ALPS Medical Breakthroughs ETF during the third quarter worth about $290,000. Finally, Commonwealth Equity Services LLC raised its holdings in ALPS Medical Breakthroughs ETF by 8.2% during the third quarter. Commonwealth Equity Services LLC now owns 18,869 shares of the company’s stock worth $568,000 after purchasing an additional 1,430 shares in the last quarter.

ALPS Medical Breakthroughs ETF Trading Up 0.0 %

NYSEARCA SBIO opened at $32.88 on Wednesday. The business’s 50 day moving average is $29.23 and its two-hundred day moving average is $30.11. ALPS Medical Breakthroughs ETF has a 12-month low of $23.58 and a 12-month high of $35.51.

ALPS Medical Breakthroughs ETF Company Profile

(Get Rating)

The ALPS Medical Breakthroughs ETF (SBIO) is an exchange-traded fund that is based on the S-Network Medical Breakthroughs index. The fund tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials. SBIO was launched on Dec 31, 2014 and is managed by ALPS.